Polymyxin B Sulfate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

31 API Suppliers, 13 USDMF, 6 CEP/COS, 2 JDMF, 1 EU WC, 2 KDMF, 20 NDC API, 20 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

FINISHED DOSAGE FORMULATIONS

145 FDF Dossiers, 95 FDA Orange Book, 7 Europe, 19 Canada, 8 South Africa, 16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

OINTMENT;OPHTHALMIC - 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM, OINTMENT;TOPICAL - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CREAM;TOPICAL - 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, OINTMENT;OPHTHALMIC - EQ 400 UNITS/GM;EQ 3.5MG BASE/GM;EQ 10,000 UNITS/GM, SOLUTION/DROPS;OPHTHALMIC - 10,000 UNITS/ML;EQ 1MG BASE/ML

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Seqens, 2 DKSH, 1 Jai Radhe Sales, 1 Gangwal Healthcare, 8 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 17 Actylis, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 24 BASF, 10 Corel Pharma Chem, 3 Finar, 9 Gangwal Chemicals, 4 Ideal Cures Pvt Ltd, 19 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 4 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nippon Fine Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 5 Roquette, 17 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives, 36 Topical, 33 Solubilizers, 22 Parenteral, 21 Controlled & Modified Release, 19 Thickeners and Stabilizers, 17 Emulsifying Agents, 15 Film Formers & Plasticizers, 11 Co-Processed Excipients, 10 Surfactant & Foaming Agents, 9 Direct Compression, 7 Fillers, Diluents & Binders, 7 Granulation, 5 Lubricants & Glidants, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 3 Taste Masking, 2 Rheology Modifiers, 2 Coloring Agents, 1 Chewable & Orodispersible Aids, 1 Disintegrants & Superdisintegrants

DIGITAL CONTENT

12 NEWS #PharmaBuzz

12 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 5 Finished Drug Prices, 1 Annual Reports

MARKET PLACE

29 APIs, 7 FDF Dossiers

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 1 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 50065 / DOSAGE - OINTMENT;OPHTHALMIC - 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
DEXAMETHASONE(UNII: 7S5I7G3JQL) (DEXAMETHASONE - UNII:7S5I7G3JQL)	DEXAMETHASONE	1mg in 1
NEOMYCIN SULFATE(UNII: 057Y626693) (NEOMYCIN - UNII:I16QD7X297)	NEOMYCIN	3.5mg in 1
POLYMYXIN B SULFATE(UNII: 19371312D4) (POLYMYXIN B - UNII:J2VZ07J96K)	POLYMYXIN B	10000[iU] in 1

Inactive Ingredients

Ingredient Name	Major Pharmaceuticals	Preferred Pharmaceuticals Inc.	Preferred Pharmaceuticals, Inc	Fera Pharmaceuticals	Preferred Pharmaceuticals, Inc.	Putney, Inc.
LANOLIN(7EV65EAW6H)
METHYLPARABEN(A2I8C7HI9T)
MINERAL OIL(T5L8T28FGP)
PETROLATUM(4T6H12BN9U)
PROPYLPARABEN(Z8IX2SC1OH)

Drug Product Composition: Polymyxin B Sulfate